Novartis heart drug's trial failure cast doubt on Amgen and Lilly's cholesterol race
What happened
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
Summary assembled by rule from the sources below